Skip to content
HowShorted

Dyne Therapeutics, Inc. short interest in 2024

In 2024, Dyne Therapeutics, Inc.'s disclosed short interest ran from 12.98% of shares outstanding on 12 Jan 2024 to 10.33% on 31 Dec 2024, a change of -2.65 percentage points. The year's high was 14.70% on 15 Apr 2024 and its low 6.84% on 30 Aug 2024, averaging 10.66% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 14.02 days on 13 Dec 2024. Full history: Dyne Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Dyne Therapeutics, Inc. in 2024

2024 in figures

Start of year
12.98% (12 Jan 2024)
End of year
10.33% (31 Dec 2024)
Change
-2.65 pp
High
14.70% (15 Apr 2024)
Low
6.84% (30 Aug 2024)
Average
10.66%
Highest days to cover
14.02 (13 Dec 2024)
SEC filings marked
8

Every report in 2024

Dyne Therapeutics, Inc. short interest in 2024
SettlementShort interestDays to coverFilings since previous
12 Jan 202412.98%1.22
31 Jan 202413.94%5.62
15 Feb 202411.81%6.68
29 Feb 202410.77%4.99
15 Mar 202411.12%3.2710-K filed, results (8-K)
28 Mar 202413.16%5.37
15 Apr 202414.70%9.96
30 Apr 202411.02%12.47
15 May 202410.71%11.8110-Q filed, results (8-K)
31 May 202411.58%4.25
14 Jun 202411.48%11.73
28 Jun 202410.39%6.04
15 Jul 202410.58%9.64
31 Jul 202411.31%11.37
15 Aug 20247.35%7.1810-Q filed, results (8-K)
30 Aug 20246.84%8.21
13 Sep 20247.63%2.76
30 Sep 20248.84%6.19
15 Oct 20249.07%11.98
31 Oct 20249.90%12.11
15 Nov 20249.98%8.1010-Q filed, results (8-K)
29 Nov 202410.17%10.42
13 Dec 202410.22%14.02
31 Dec 202410.33%11.24

See also: Dyne Therapeutics, Inc.'s full history · most shorted US stocks of 2024 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.